These results push the line forward to the contribution of PARP inhibitors to reduced tumor burden in lung adenocarcinoma through the action of three major biological mechanisms, namely DNA damage, oxidative stress, and apoptosis. The gene discussed is PARP1; the disease is neoplasm.